FDA and the Critical Path to Twenty-first-century Medicine
Center for Medicine in the Public Interest, New York, USA
Address correspondence to: Peter J. Pitts, Center for Medicine in the Public Interest, 308 East 38th Street, Suite 201, New York, NY 10016, USA. E-mail: ppitts{at}cmpi.org
 |
Abstract |
|---|
One of the most pressing issues that confronts the Food and Drug Administration (FDA) is learning how to better address and assist in medical product development. FDA needs to prepare today so the agency can efficiently evaluate the technologies of tomorrow. Clearly, this is an area that impacts not only health care consumers but also our economies and financial markets. If the FDA can be a more aggressive part of the solution, they can help not only ease some of the pressures that are driving up health care costs but also help all of us to maximize the value of medical innovations. The high cost of research and development is forcing many companies to make the short-term business decision to focus product development on those molecules that have a much higher potential to recoup expenditures. Unfortunately, this trumps attempts to develop potentially risky but breakthrough products for diseases affecting smaller populations, the orphan drugs. FDA's critical path initiative will enable innovative growth companies to better and more efficiently attack the steep hurdles facing them, allowing them to compete more effectively against the bigger, better-funded players in the market on a more level playing field. That means a real change in the risk/benefit equation for both the emerging growth companies and the public health.
Keywords: FDA, innovation, medical devices, pharmaceuticals, research and development
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. S. Iltis and M. J. Cherry First Do No Harm: Critical Analyses of the Roads to Health Care Reform J Med Philos, October 1, 2008; 33(5): 403 - 415. [Abstract] [Full Text] [PDF]
|
|